Sorafenib inhibits tumor growth and improves survival in a transgenic mouse model of pancreatic islet cell tumors.

In line with the tumor size reduction, the pancreas weight of Sorafenib-treated mice decreased (0.145 ± 0.19 g versus 0.192 ± 0.15 g, P = 0.053), but failed to reach statistical significance (see also Figure 3(a) ).

also in 6,035 other papers

In response to Sorafenib VEGF-expression increased, although the difference was not quite statistically significant (see Figure 3(c3) ). 3.2.

also in 341 other papers